Dual action of cyclin-dependent kinase inhibitors: Induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin

Polish Journal of Pharmacology

Volumn 55, Issue 5, 2003, Pages 895-902

  Wesierska Gadek, Józefa ^a   Gueorguieva, Marieta ^a   Horky, Marcel ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Apoptosis; Caspases 3 reconstitution; FACS analysis; G2 M arrest; MCF 7 cells; p53 nuclear accumulation; p53 up regulation; PARP 1 cleavage 3

Indexed keywords

CALCIUM CHANNEL; CASPASE 3; CISPLATIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE INHIBITOR; NEUROTRANSMITTER; PROTEIN P53; ROSCOVITINE;

APOPTOSIS; ARTICLE; BRAIN NERVE CELL; BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME STRUCTURE; ENZYME SUBUNIT; GENE EXPRESSION; GENE MUTATION; GROWTH INHIBITION; GROWTH REGULATION; HUMAN; HUMAN CELL; MITOSIS; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; OXIDATIVE STRESS; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; STRUCTURE ANALYSIS; UPREGULATION;

APOPTOSIS; CASPASE 3; CASPASES; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CISPLATIN; CYCLIN-DEPENDENT KINASE 5; CYCLIN-DEPENDENT KINASES; G2 PHASE; HUMANS; NEURONS; PURINES; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 0346327392     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Bargonetti J., Manfredi J.J.: Multiple roles of the tumor suppressor p53. Curr. Opin. Oncol., 2002, 14, 86-91.
2. Blagosklonny M.V.: P53: an ubiquitous target of anti-cancer drugs. Int. J. Cancer, 2002, 98, 161-166.
3. WAF/CIP1 and p53 and protects p21-sensitive cells from paclitaxel. Cancer Biol. Ther., 2002, 1, 420-425.
4. Blagosklonny M.V., Demidenko Z.N., Fojo T.: Inhibition of transcription results in accumulation of Wt p53 followed by delayed outburst of p53-inducible proteins: p53 as a sensor of transcriptional integrity. Cell Cycle, 2002, 1, 67-74.
5. Blagoskonny M.V., Pardee A.B.: Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res., 2001, 61, 4301-4305.
6. Blanc C., Deveraux Q.L., Krajewski S., Janicke R.U., Porter A.G., Redd J., Jaggi R., Marti A.: Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Res., 2000, 60, 4386-4390.
7. Cohen S.M., Lippard S.J.: Cisplatin: from DNA damage to cancer chemotherapy. Prog. Nucleic Acids Res. Mol. Biol., 2001, 67, 93-130.
8. David-Pfeuty D.: Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor derived cells. Oncogene, 1999, 18, 7409-7422.
9. David-Pfeuty D., Nouvian-Dooghe Y., Sirri V., Roussel P., Hernandez-Verdun D.: Common and reversible regulation of wild-type p53 function and of ribosomal biogenesis by protein kinases in human cells. Oncogene, 2001, 20, 5951-5963.
10. De Azevedo W.F., Leclerc S., Meijer L., Havlicek L., Strnad M., Kim S.H.: Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem., 1997, 243, 518-526.
11. Edamatsu H., Gau C.L., Nemoto T., Guo L., Tamanoi F.: Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene, 2000, 27, 3059-3068.
12. Gray N., Detivaud L., Doerig C., Meijer L.: ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem., 1999, 6, 859-875.
13. He Q., Liang C.H., Lippard S.J.: Steroid hormones induce HMG1 overexpression and sensitize breast cancer to cisplatin and carboplatin. Proc. Nat. Acad. Sci. USA, 2000, 97, 5768-5772.
14. Jänicke R.U., Sprengart M.L., Wati M.R., Porter A.G.: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem., 1998, 273, 9357-9360.
15. Jordan P., Carmo-Fonseca M.: Molecular mechanisms involved in cisplatin cytotoxicity. Cell. Mol. Life Sci., 2000, 57, 1229-1235.
16. Ljungman M., Paulsen M.T.: The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol. Pharmacol., 2001, 60, 785-789.
17. Lövborg H., Wojciechowski J., Larsson R., Wesierska-Gadek J.: Action of a novel anticancer agent, CHS 828 on mouse fibroblasts: increased sensitivity of cells lacking poly(ADP-ribose)polymerase-1. Cancer Res., 2002, 62, 4206-4211.
18. Meijer L., Borgne A., Mulner O., Chong J.P., Blow J.J., Inagaki N., Inaga M., Delcros J.G., Moulinoux J.P.: Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem., 1997, 243, 527-536.
19. Mgbonyebi O.P., Russo J., Russo I.H.: Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res., 1999, 59, 1903-1910.
20. Nurse P.: Cyclin dependent kinases and cell cycle control (Nobel lecture). Chembiochem, 2002, 3, 596-603.
21. Tam S.W., Shay J.W., Pagano M.: Differential expression and cell cycle regulation of the cyclin dependent kinase 4 inhibitor p16Ink4. Cancer Res., 1994, 54, 5816-5820.
22. Vindelov L.L., Christensen I.J., Keiding N., Spang-Thomsen M., Nissen N.I.: Long-term storage of samples for flow cytometric DNA analysis. Cytometry, 1983, 3, 317-322.
23. Vitali L., Yakisich J.S., Vita M.F., Fernandez A., Settembrini L., Siden A., Cruz M., Carminatti H., Casas O., Vargas V.I.: Roscovitine inhibits ongoing DNA synthesis in human cervical cancer. Cancer Lett., 2002, 1, 7-12.
24. Wesierska-Gadek J., Schloffer D., Kotala V., Horky M.: Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy. Int. J. Cancer, 2002, 101, 128-136.
25. Wesierska-Gadek J., Schmid G.: Overexpressed poly(ADP-ribose)polymerase delays the release of rat cells from p53-mediated G1 checkpoint. J. Cell. Biochem., 2000, 80, 85-103.
26. Wesierska-Gadek J., Wang Z.-Q., Schmid G.: Reduced stability of regularly spliced but not alternatively spliced p53 protein in PARP-deficient mouse fibroblasts. Cancer Res., 1999, 59, 28-34.
27. Wojciechowski J., Horky M., Gueorguieva M., Wesierska-Gadek J.: Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int. J. Cancer, 2003, 106, 486-495.
28. Yakisich J.S., Boethius J., Lindblom I.O., Wallstedt L., Vargas V.I., Siden A., Cruz M.H.: Inhibition of DNA synthesis in human gliomas by roscovitine. NeuroReport, 1999, 12, 2563-2567.